The clinical performance is complex and often involves multi-system fatigue. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological evaluation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of MDS-related prognosis requires individualized management, typically including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of EB2 proliferation of stem cells associated with MDS. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.